ZDHHC7

Across TCGA pan-cancer cohorts, ZDHHC7 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZDHHC7 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ZDHHC7 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZDHHC7 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where ZDHHC7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.730	0.946	.011	15	view →
PDAC	DFS	Median	IV	0.250	0.785	.010	6	view →
LUAD	OS	Quartile	III,IV	0.861	0.321	.022	4	view →
GBM	OS	Median	All	0.215	0.586	.019	2	view →
HNSC	DFS	Median	III,IV	0.760	1.000	.019	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZDHHC7–CCRCC (DFS)

Open the CCRCC breakdown →